Literature DB >> 19171798

Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection.

Thomas A Toni1, Eugene L Asahchop, Daniela Moisi, Michel Ntemgwa, Maureen Oliveira, Bernard Masquelier, Bluma G Brenner, Mark A Wainberg.   

Abstract

We used an allele-specific real-time PCR assay to explore the presence of K103N and M184V minority species among primary human immunodeficiency virus (HIV) infections and their potential influence in HIV transmission. Thirty randomly chosen antiretroviral drug-naive patients lacking both the K103N and the M184V mutations as determined by conventional sequencing methods were studied, and K103N and M184V viral minority species were found in three (10%) and four (11%) patients, respectively.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19171798      PMCID： PMC2663097          DOI： 10.1128/AAC.01494-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis.

Authors:  Xin Wei; Chen Liang; Matthias Götte; Mark A Wainberg
Journal:  Virology       Date:  2003-06-20       Impact factor: 3.616

2.  Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.

Authors:  H Salomon; M A Wainberg; B Brenner; Y Quan; D Rouleau; P Coté; R LeBlanc; E Lefebvre; B Spira; C Tsoukas; R P Sekaly; B Conway; D Mayers; J P Routy
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

3.  Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinic.

Authors:  Jessica R Grubb; Ekachai Singhatiraj; Kristin Mondy; William G Powderly; Edgar T Overton
Journal:  AIDS       Date:  2006-10-24       Impact factor: 4.177

Review 4.  HIV transmission and primary drug resistance.

Authors:  Dan Turner; Mark A Wainberg
Journal:  AIDS Rev       Date:  2006 Jan-Mar       Impact factor: 2.500

5.  Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.

Authors:  Emanuele Nicastri; Loredana Sarmati; Gabriella d'Ettorre; Lucia Palmisano; Saverio G Parisi; Ilaria Uccella; Alessia Rianda; Ercole Concia; Vincenzo Vullo; Stefano Vella; Massimo Andreoni
Journal:  J Med Virol       Date:  2003-01       Impact factor: 2.327

6.  Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.

Authors:  L Bacheler; S Jeffrey; G Hanna; R D'Aquila; L Wallace; K Logue; B Cordova; K Hertogs; B Larder; R Buckery; D Baker; K Gallagher; H Scarnati; R Tritch; C Rizzo
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

7.  Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity.

Authors:  Karidia Diallo; Bruno Marchand; Xin Wei; Luciano Cellai; Matthias Götte; Mark A Wainberg
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions.

Authors:  Karin J Metzner; Sebastian Bonhoeffer; Marek Fischer; Rose Karanicolas; Kristina Allers; Beda Joos; Rainer Weber; Bernard Hirschel; Leondios G Kostrikis; Huldrych F Günthard
Journal:  J Infect Dis       Date:  2003-11-03       Impact factor: 5.226

9.  Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003.

Authors:  Bernard Masquelier; Krishnan Bhaskaran; Deenan Pillay; Robert Gifford; Eric Balestre; Louise Bruun Jørgensen; Court Pedersen; Lia van der Hoek; Maria Prins; Claudia Balotta; Benedetta Longo; Claudia Kücherer; Gabriele Poggensee; Marta Ortiz; Carmen de Mendoza; John Gill; Hervé Fleury; Kholoud Porter
Journal:  J Acquir Immune Defic Syndr       Date:  2005-12-15       Impact factor: 3.731

10.  Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.

Authors:  Jeffrey A Johnson; Jin-Fen Li; Xierong Wei; Jonathan Lipscomb; David Irlbeck; Charles Craig; Amanda Smith; Diane E Bennett; Michael Monsour; Paul Sandstrom; E Randall Lanier; Walid Heneine
Journal:  PLoS Med       Date:  2008-07-29       Impact factor: 11.069
View more
  15 in total

1.  Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants.

Authors:  Sara Gianella; Wayne Delport; Mary E Pacold; Jason A Young; Jun Yong Choi; Susan J Little; Douglas D Richman; Sergei L Kosakovsky Pond; Davey M Smith
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

Review 3.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

4.  Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus.

Authors:  Julie Sheldon; Nathan M Beach; Elena Moreno; Isabel Gallego; David Piñeiro; Encarnación Martínez-Salas; Josep Gregori; Josep Quer; Juan Ignacio Esteban; Charles M Rice; Esteban Domingo; Celia Perales
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

5.  Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.

Authors:  Lisa L Ross; Winkler G Weinberg; Edwin DeJesus; Margaret A Fischl; Joseph H Horton; Keith A Pappa; C Tracey Lancaster; Gary E Pakes; Kimberly Y Smith
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

Review 6.  HIV-1 treatment as prevention: the good, the bad, and the challenges.

Authors:  Kumi Smith; Kimberly A Powers; Angela D M Kashuba; Myron S Cohen
Journal:  Curr Opin HIV AIDS       Date:  2011-07       Impact factor: 4.283

7.  Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.

Authors:  Thomas A Toni; Bluma G Brenner; Eugene L Asahchop; Michel Ntemgwa; Daniella Moisi; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

8.  Differential persistence of transmitted HIV-1 drug resistance mutation classes.

Authors:  Vivek Jain; Maria C Sucupira; Peter Bacchetti; Wendy Hartogensis; Ricardo S Diaz; Esper G Kallas; Luiz M Janini; Teri Liegler; Christopher D Pilcher; Robert M Grant; Rodrigo Cortes; Steven G Deeks; Frederick M Hecht
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

9.  Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1-Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing.

Authors:  Dana S Clutter; Shuntai Zhou; Vici Varghese; Soo-Yon Rhee; Benjamin A Pinsky; W Jeffrey Fessel; Daniel B Klein; Ean Spielvogel; Susan P Holmes; Leo B Hurley; Michael J Silverberg; Ronald Swanstrom; Robert W Shafer
Journal:  J Infect Dis       Date:  2017-08-01       Impact factor: 5.226

10.  Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of Hypermutation.

Authors:  Kenny Dauwe; Delfien Staelens; Leen Vancoillie; Virginie Mortier; Chris Verhofstede
Journal:  J Clin Microbiol       Date:  2016-04-13       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.